



## Company profile

Dermapharm is a fast-growing manufacturer of branded pharmaceuticals. Founded in 1991, the company is based in Grünwald near Munich. In addition to the main site in Brehna near Leipzig, Dermapharm operates further production, development and sales sites within Europe, primarily in Germany. Dermapharm currently employs more than 2,500 people worldwide..


## Reasons to invest

1. Clear focus on Germany as a business location
2. Rapidly growing pharmaceutical manufacturer in selected niche markets
3. Own R&D
4. Pipeline with approximately 40 development projects
5. Successful track record in acquisitions
6. Expansion of international presence


## Key figures

		H1 2022	H1 2021	2021	2020	2019
Revenue	EUR million	471.1	427.8	942.9	793.8	700.9
Adjusted EBITDA	EUR million	148.7	137.0	351.1	200.7	177.6
Adjusted EBITDA-margin	%	31.6	32.0	37.2	25.3	25.3
Unadjusted EBITDA	EUR million	142.6	134.6	354.4	184.5	168.5
Unadjusted EBITDA-margin	%	30.3	31.5	37.6	23.2	24.0
Operating income	EUR million	91.0	112.0	298.5	136.9	119.5
Earnings before taxes	EUR million	87.2	108.7	293.0	125.3	110.1
Profit or (loss) for the period	EUR million	51.6	75.8	208.9	85.9	77.8
Earnings per share	EUR	0.96	1.41	3.89	1.59	1.43


## Revenue by segments (in EUR million)



## EBITDA by segments (in EUR million)



## Adjusted EBITDA-margin (in %)



## 2022 guidance

### Group revenue growth:

**10% to 13%**

vs. previous year (EUR 942,9 million)

### Group EBITDA growth:

**3% to 7%**

vs. previous year (EUR 351,1 million)



## Dermapharm reports in three segments

### Branded pharmaceuticals and other healthcare products

With more than 380 active pharmaceutical ingredients, Dermapharm markets more than 1,200 marketing authorisations. The range of medicinal products, medical devices and food supplements is specialised in selected therapeutic areas in which Dermapharm occupies a leading market position, particularly in Germany.

### Herbal extracts

In the "Herbal Extracts" segment, Dermapharm has a globally leading manufacturer of plant extracts and herbal active ingredients for the pharmaceutical, nutraceutical, food and cosmetics industries in the form of the Spanish company Euromed S.A and the market leader for dronabinol in Germany in the form of the C<sup>3</sup> Group..

### Parallelimportgeschäft

Dermapharm's business model also includes a "parallel import business" segment, which is operated under the "axicorp" brand. Based on turnover, axicorp was in the top-4 of the strongest parallel importers in Germany in H1/2022.


## Facts about Dermapharm share

<b>Ticker symbol:</b>	DMP
<b>Ticker symbol Bloomberg:</b>	DMP:GR
<b>Ticker symbol Reuters:</b>	DMPG.DE
<b>WKN   ISIN:</b>	A2GS5D   DE000A2GS5D8
<b>Number of shares:</b>	53.84 million
<b>IPO:</b>	9 February 2018


## Shareholder structure

(unchanged since 15 October 2020)

Free float  
34.95 %



## Dermapharm share in comparison



## Financial calendar

### 16 November 2022

Publication of Q3 Quarterly Report

### 22 November 2022

Capital Markets Day

### Notice:

This publication contains various statements concerning the future development of the Dermapharm Group. These statements are based on both assumptions and estimates. Our assumptions involve risks and uncertainties that could cause actual results to differ materially from those anticipated. There are no plans to update the forward-looking statements. Throughout this publication, apparent differences may occur due to mathematical rounding during addition.